5 January 2026 China Pharma and Biotech China Pharma and Biotech 2026 Outlook: Off to the races Rebecca Liang, Ph.D. +852 2123 2656 rebecca.liang@bernsteinsg.com Ellie Li +852 2123 2621 ellie.li@bernsteinsg.com "The stock market is a device for transferring money from the impatient to the patient." Positive outlook at sector level: valuation-wise we're back in a more rational range than July - Aug, with most stocks dialing back 20-30%. The major healthcare and biotech indices are below the price levels of 2 ...

The healthcare sector was a contrarian pick for SoFi's Liz Thomas this year, that could come into its own in 2026. - Getty Images Year-end angst just keeps hitting investors, with no signs of dip-buying after Monday’s selloff. Blame jitters over AI and fading rate-cut hopes from the Fed. Tech — rather AI — has become the big sexy call of 2025 that is haunting investors, who have done pretty well sticking to that. But is it time to start thinking about alternatives? Our call of the day from fintech SoFi’s ...

Company Overview - Eli Lilly and Company is represented by Lucas Montarce, CFO, and Mike Czapar, SVP of Investor Relations, during the BofA Securities 2025 Health Care Conference [1][2]. Industry Context - The discussion includes insights on drug pricing policies, particularly referencing the potential impact of political actions, such as those from former President Trump, on the pharmaceutical industry [3]. Financial Leadership - Lucas Montarce has been with Eli Lilly since 2021 and has held the CFO position since September 2024, indicating a strong leadership presence in both U.S. and international roles [1].